Last reviewed · How we verify
Delamanid (DLM)
Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis.
Delamanid inhibits mycobacterial cell wall synthesis by targeting mycolic acid production, thereby killing Mycobacterium tuberculosis. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB), Pulmonary tuberculosis in combination with other anti-TB agents.
At a glance
| Generic name | Delamanid (DLM) |
|---|---|
| Sponsor | Wuhan Pulmonary Hospital |
| Drug class | Mycobacterial cell wall synthesis inhibitor |
| Target | DprE1 (decaprenylphosphoryl-β-D-ribose 2'-epimerase) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Delamanid is a prodrug that is activated by mycobacterial enzymes to form reactive intermediates that inhibit the DprE1 enzyme, which is essential for the synthesis of mycolic acids—critical components of the mycobacterial cell wall. By disrupting cell wall integrity, delamanid leads to bacterial death and is particularly effective against drug-resistant tuberculosis strains.
Approved indications
- Drug-resistant tuberculosis (MDR-TB and XDR-TB)
- Pulmonary tuberculosis in combination with other anti-TB agents
Common side effects
- Peripheral neuropathy
- QT prolongation
- Gastrointestinal disturbances
- Hepatotoxicity
Key clinical trials
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- 6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province (NA)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2, PHASE3)
- Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort (PHASE3)
- Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis (PHASE2)
- A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis (NA)
- Linezolid Dosing Strategies in Drug-Resistant TB (PHASE2)
- Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |